TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.

Neuro Oncol

Department of Pediatrics, Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, Texas, USA.

Published: June 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159445PMC
http://dx.doi.org/10.1093/neuonc/noac048DOI Listing

Publication Analysis

Top Keywords

trk inhibition
4
inhibition pediatric
4
pediatric adult
4
adult central
4
central nervous
4
nervous system
4
system tumors
4
tumors early
4
early promise
4
promise future
4

Similar Publications

Background: Recent studies have implicated a role for perioperative medications in determining patient outcomes after surgery for malignant tumours, including relapse and metastasis.

Methods: A combined approach spanned molecular, cellular, and organismal levels, including bioinformatics, immunohistochemical staining of clinical and animal samples, RNA sequencing of glioblastoma multiforme (GBM) cells with Ingenuity Pathway Analysis, lentiviral-mediated gene expression modulation, in vitro cell experiments, and in vivo orthotopic tumour transplantation.

Results: We observed a significant correlation between increased kappa opioid receptor (KOP receptor) expression and better prognosis in patients with glioma.

View Article and Find Full Text PDF

NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1.

BMC Cancer

December 2024

Institute of Integrative Medicine, Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.

Background: The NTRK fusion gene is a rare cancer driver and a typical representative "diamond mutation". Its unique role in tumor progression is highly important for the clinical diagnosis and treatment of patients with tumors. We searched for NTRK fusion-positive patients in our hospital.

View Article and Find Full Text PDF

Targeted intervention in nerve-cancer crosstalk enhances pancreatic cancer chemotherapy.

Nat Nanotechnol

November 2024

National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.

Article Synopsis
  • * Researchers developed a novel therapy using E. coli-derived outer membrane vesicles with a nerve-binding peptide and a Trk inhibitor to specifically target tumor-associated nerves.
  • * This approach effectively disrupts nerve signaling and alters macrophage behavior, reducing nerve growth and enhancing chemotherapy effectiveness against pancreatic cancer.
View Article and Find Full Text PDF

Acyclic sesquiterpenes nerolidol and farnesol: mechanistic insights into their neuroprotective potential.

Pharmacol Rep

October 2024

University Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, 140413, India.

Sesquiterpenes are a class of organic compounds found in plants, fungi, and some insects. They are characterized by the presence of three isoprene units, resulting in a molecular formula that typically contains 15 carbon atoms (C₁₅H₂₄). Nerolidol and farnesol are both sesquiterpene alcohols present in the essential oils of numerous plants.

View Article and Find Full Text PDF

fusions are oncogenic drivers for multiple tumor types. Therefore, the development of selective tropomyosin receptor kinase (TRK) inhibitors, including larotrectinib and entrectinib, has been transformative in the context of clinical management, given the high rates of responses to these drugs, including intracranial responses in patients with brain metastases. Given their promising activity in pan-cancer cohorts, larotrectinib and entrectinib received U.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!